Akt1 and Akt2 Play Distinct Roles in the Initiation and Metastatic Phases of Mammary Tumor Progression

Overview

Journal Cancer Res

Specialty Oncology

Date 2009 Jun 4

PMID 19491266

Citations 108

Authors

Rachelle L Dillon

Richard Marcotte

Bryan T Hennessy

James R Woodgett

Gordon B Mills

William J Muller

Affiliations

Soon will be listed here.

Abstract

The phosphatidylinositol 3-kinase (PI3K)/Akt survival pathway is often dysregulated in cancer. Our previous studies have shown that coexpression of activated Akt1 with activated ErbB2 or polyoma virus middle T antigen uncoupled from the PI3K pathway (PyVmT Y315/322F) accelerates mammary tumor development but cannot rescue the metastatic phenotype associated with these models. Here, we report the generation of transgenic mice expressing activated Akt2 in the mammary epithelium. Like the mouse mammary tumor virus-Akt1 strain, mammary-specific expression of Akt2 delayed mammary gland involution. However, in contrast to Akt1, coexpression of Akt2 with activated ErbB2 or PyVmT Y315/322F in the mammary glands of transgenic mice did not affect the latency of tumor development. Strikingly, Akt2 coexpresssion markedly increased the incidence of pulmonary metastases in both tumor models, demonstrating a unique role in tumor progression. Together, these observations argue that these highly conserved kinases have distinct biological and biochemical outputs that play opposing roles in mammary tumor induction and metastasis.

Citing Articles

AKT kinases as therapeutic targets.

Hassan D, Menges C, Testa J, Bellacosa A J Exp Clin Cancer Res. 2024; 43(1):313.

PMID: 39614261 PMC: 11606119. DOI: 10.1186/s13046-024-03207-4.

Down-Regulation of AKT Proteins Slows the Growth of Mutant-KRAS Pancreatic Tumors.

Chen C, Jiang Y, You I, Gray N, Lin R Cells. 2024; 13(12.

PMID: 38920688 PMC: 11202146. DOI: 10.3390/cells13121061.

Down-regulation of AKT proteins slows the growth of mutant-KRAS pancreatic tumors.

Chen C, Jiang Y, You I, Gray N, Lin R bioRxiv. 2024; .

PMID: 38746217 PMC: 11092743. DOI: 10.1101/2024.05.03.592345.

Substrate preference of protein kinase B isoforms can vary depending on the cell line.

Palma M, Perez S, Husain A, Bhandari D PLoS One. 2024; 19(3):e0298322.

PMID: 38502658 PMC: 10950239. DOI: 10.1371/journal.pone.0298322.

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK).

Huang X, You L, Nepovimova E, Psotka M, Malinak D, Valko M J Enzyme Inhib Med Chem. 2023; 38(1):2237209.

PMID: 37489050 PMC: 10392309. DOI: 10.1080/14756366.2023.2237209.

References

Dilworth S, Griffin B . Monoclonal antibodies against polyoma virus tumor antigens. Proc Natl Acad Sci U S A. 1982; 79(4):1059-63. PMC: 345899. DOI: 10.1073/pnas.79.4.1059. View

Schwertfeger K, Richert M, Anderson S . Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol. 2001; 15(6):867-81. DOI: 10.1210/mend.15.6.0663. View

Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt P . The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci U S A. 1998; 95(25):14950-5. PMC: 24556. DOI: 10.1073/pnas.95.25.14950. View

Andrechek E, Laing M, Girgis-Gabardo A, Siegel P, Cardiff R, Muller W . Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res. 2003; 63(16):4920-6. View

Schwertfeger K, McManaman J, Palmer C, Neville M, Anderson S . Expression of constitutively activated Akt in the mammary gland leads to excess lipid synthesis during pregnancy and lactation. J Lipid Res. 2003; 44(6):1100-12. DOI: 10.1194/jlr.M300045-JLR200. View

Kurokawa H, Arteaga C . ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res. 2003; 9(1 Pt 2):511S-5S. View

Hutchinson J, Jin J, Cardiff R, Woodgett J, Muller W . Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 2004; 64(9):3171-8. DOI: 10.1158/0008-5472.can-03-3465. View

DILLON R, White D, Muller W . The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene. 2007; 26(9):1338-45. DOI: 10.1038/sj.onc.1210202. View

Tokunaga E, Kataoka A, Kimura Y, Oki E, Mashino K, Nishida K . The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. Eur J Cancer. 2006; 42(5):629-35. DOI: 10.1016/j.ejca.2005.11.025. View

10.

Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills G . Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006; 5(10):2512-21. DOI: 10.1158/1535-7163.MCT-06-0334. View

11.

Siegel P, Ryan E, Cardiff R, Muller W . Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 1999; 18(8):2149-64. PMC: 1171299. DOI: 10.1093/emboj/18.8.2149. View

12.

Maroulakou I, Oemler W, Naber S, Klebba I, Kuperwasser C, Tsichlis P . Distinct roles of the three Akt isoforms in lactogenic differentiation and involution. J Cell Physiol. 2008; 217(2):468-77. PMC: 2871282. DOI: 10.1002/jcp.21518. View

13.

Hutchinson J, Jin J, Cardiff R, Woodgett J, Muller W . Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol. 2001; 21(6):2203-12. PMC: 86854. DOI: 10.1128/MCB.21.6.2203-2212.2001. View

14.

Schiff R, Massarweh S, Shou J, Bharwani L, Mohsin S, Osborne C . Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004; 10(1 Pt 2):331S-6S. DOI: 10.1158/1078-0432.ccr-031212. View

15.

Johnston S . Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res. 2005; 11(2 Pt 2):889s-99s. View

16.

Ackler S, Ahmad S, Tobias C, Johnson M, Glazer R . Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene. 2002; 21(2):198-206. DOI: 10.1038/sj.onc.1205052. View

17.

Johnston S, Head J, Pancholi S, Detre S, Martin L, Smith I . Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res. 2003; 9(1 Pt 2):524S-32S. View

18.

Price J, Polyzos A, Zhang R, Daniels L . Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 1990; 50(3):717-21. View

19.

Webster M, Hutchinson J, Rauh M, Muthuswamy S, Anton M, Tortorice C . Requirement for both Shc and phosphatidylinositol 3' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol. 1998; 18(4):2344-59. PMC: 121489. DOI: 10.1128/MCB.18.4.2344. View

20.

Maroulakou I, Oemler W, Naber S, Tsichlis P . Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res. 2007; 67(1):167-77. DOI: 10.1158/0008-5472.CAN-06-3782. View